We discovered through a multiple cohort survival study that patients with high expression levels of MAP2K3 had shorter overall survival, regardless of whether they had high- (Figures 4A–I) or low-grade gliomas (Figures 4J–N). This evidence concerns the gene MAP2K3 and central nervous system cancer.